![most intense i doser doses most intense i doser doses](https://i.redd.it/220mgxxditw41.jpg)
Healthcare providers should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. These events may be associated with the reduction of oral corticosteroid therapy. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.Įosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Some patients reported visual disturbances (e.g., blurred vision) associated with conjunctivitis or keratitis. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Conjunctivitis also occurred more frequently in chronic rhinosinusitis with nasal polyposis subjects who received DUPIXENT compared to those who received placebo. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.Ĭonjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT versus placebo, with conjunctivitis being the most frequently reported eye disorder.
![most intense i doser doses most intense i doser doses](https://1.bp.blogspot.com/-IK6GvBDIOe0/YM1Ys1vKo4I/AAAAAAAAAPM/DeEhf5-ULpcisUCQdjgNp977WN-kfVIgACNcBGAsYHQ/w1200-h630-p-k-no-nu/pexels-cottonbro-3952224.jpg)
Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported.
![most intense i doser doses most intense i doser doses](https://i.pinimg.com/736x/e2/0c/b0/e20cb0ccb5bd8d38f79171fca79c9957.jpg)
CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.